Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4932 - HOXA-related long non-coding RNAs impact prognosis in early stage NSCLC patients


09 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Non-Small Cell Lung Cancer


Alfons Navarro


Annals of Oncology (2017) 28 (suppl_5): v453-v456. 10.1093/annonc/mdx381


A. Navarro1, S. Santasusagna1, N. Vinolas Segarra2, J.J. Castellano1, J. Moises3, S. Morales1, J. Canals1, C. Muñoz1, J. Ramírez4, R.M. Marrades3, L. Molins5, M. Monzo1

Author affiliations

  • 1 Molecular Oncology And Embryology Laboratory, Human Anatomy Unit, University of Barcelona, 08036 - Barcelona/ES
  • 2 Medical Oncology, Hospital Clinic y Provincial de Barcelona, 8036 - Barcelona/ES
  • 3 Pneumology, Hospital Clinic y Provincial de Barcelona, 8036 - Barcelona/ES
  • 4 Pathology, Hospital Clinic y Provincial de Barcelona, 8036 - Barcelona/ES
  • 5 Thoracic Surgery, Hospital Clinic y Provincial de Barcelona, 8036 - Barcelona/ES


Abstract 4932


HOX genes, grouped in four clusters in humans (HOXA-D), encode for transcription factors that are master regulators of embryonic development and oncogenesis. HOXA cluster, located in chromosome 7, play a critical role in the patterning of tissues with mesodermal components such as lungs. Long non-coding RNAs (lncRNAs) are especially abundant in the HOXA cluster (HOXA10-AS, HOXAS2, HOXAS3, HOXA11-AS, HOTAIRM1 and HOTTIP). We aimed to evaluate the prognostic role of HOXA-related lncRNAs in early stage non-small cell lung cancer (NSCLC).


100 early stage NSCLC patients resected in our center from June 2007 to November 2013 were studied. Patient characteristics: median age, 65 (32-84); 78% males; 74% stage I; 56% ADK; 23% received adjuvant treatment. With a mean follow-up of 28.7 months, 31% relapsed. As validation data set 200 NSCLC patients from TCGA Research Network were used (RNAseq data). Only stage I-II TCGA samples without prior malignancy or synchronous cancer that not received neoadjuvant treatment were included. Statistical analysis was performed using R and TANRIC.


HOTTIP and HOXA11AS impacted prognosis in our cohort of patients. HOTTIP was expressed in all samples and patients with high levels of HOTTIP had shorter TTR (78.3 vs 58 months; p = 0.048) and shorter OS (81.2 vs 61 months; p = 0.023). HOTTIP was overexpressed in SCC (p = 0.007) and in smokers (p = 0.018). HOXA11AS was expressed only in 9% of patients but the patients expressing HOXA11AS had shorter TTR (73.5 vs 32 months; p = 0.002). In the multivariate analysis HOXA11AS emerged as an independent prognostic marker for TTR (OR: 3.13, 95%CI: 1.3-7.3; p = 0.009), while HOTTIP (OR: 2.357, 95%CI: 1.1-5.2; p = 0.036) and age>65 (p = 0.022) for OS. In the validation data set HOXA11AS was validated as prognostic marker (p = 0.019). HOXA11AS expression correlated positively with development genes HOXA11, HOXA13, HOXA10, HOXA9, HOXA3, FOXD1, ZIC5 and miR-196b (HOXA cluster miRNA) and negatively with surfactant metabolism genes SFTPB and NAPSA or let-7a(p 


HOXA11AS expression in early stage NSCLC patients is a high-risk relapse marker.

Clinical trial identification

Legal entity responsible for the study

University of Barcelona, Barcelona, Spain




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.